Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
Dr. Nolan Williams discusses cutting-edge psychiatric treatments including TMS, psilocybin, MDMA, ketamine, ibogaine, and ayahuasca, framing them within a 'Psychiatry 3.0' paradigm that focuses on brain circuit recalibration rather than chemical imbalances. He explains how his Stanford Neuromodulation Therapy (SNT) achieves 60-90% remission rates in depression within five days using spaced learning theory. The conversation challenges the serotonin deficiency model of depression and highlights convergent mechanisms between psychedelics and TMS.
Summary
Dr. Nolan Williams, a dual-trained neurologist and psychiatrist at Stanford, opens by situating depression as the world's most disabling condition and a newly recognized fourth major risk factor for coronary artery disease, alongside hypertension, hyperlipidemia, and diabetes. He describes research demonstrating a direct brain-heart connection, where TMS stimulation of the dorsolateral prefrontal cortex propagates through the anterior cingulate, insula, amygdala, nucleus tractus solitarius, and into the vagus nerve, measurably decelerating heart rate.
Williams introduces a conceptual framework he calls 'Psychiatry 3.0,' contrasting it with earlier paradigms. Psychiatry 1.0 centered on psychoanalytic and experiential explanations (e.g., the schizophrenogenic mother), while Psychiatry 2.0 promoted the chemical imbalance/serotonin deficiency hypothesis. He argues that both were disempowering for patients. Psychiatry 3.0 reframes mental illness as circuit-level dysfunction — recalibratable, recoverable, and not indicative of permanent deficit. He notes that SSRIs do work for a subpopulation but likely not through direct serotonin replacement, given their delayed onset, suggesting neuroplasticity as the more likely mechanism.
The core of Williams' TMS work centers on the Stanford Neuromodulation Therapy (SNT), formerly SAINT. He explains that traditional TMS protocols (once daily for six weeks) failed to leverage spaced learning theory. SNT reorganizes stimulation into 10 sessions per day over five days — effectively delivering seven and a half months' worth of stimulation in a condensed block. This approach yields 60-90% full remission rates in depression, with some patients maintaining remission for years. He describes patients, once remitted mid-week, spontaneously reporting profound present-moment awareness — a mindfulness-like state they had never previously achieved.
On psychedelics, Williams reviews neuroimaging findings by David Nutt and Robin Carhart-Harris showing that psilocybin paradoxically decreases overall brain activity while increasing global connectivity — expanding what he calls 'small world' to 'large world' brain connectivity. He notes a convergent mechanism between psilocybin and SNT: both down-regulate connectivity between the subgenual anterior cingulate (negative mood state) and the default mode network (self-representation), effectively uncoupling a negatively valenced self-referential loop associated with depression.
For MDMA-assisted therapy in PTSD, Williams cites the MAPS trials published in Nature Medicine, where approximately two-thirds of participants showed clinically significant PTSD improvement after one to two sessions of 150-175mg MDMA, with effects lasting potentially years. For psilocybin in depression, open-label studies show 50-67% improvement rates; blinded trials show roughly one-third improvement. Ketamine, by contrast, produces shorter-lasting effects averaging about ten days per infusion.
Williams discusses ibogaine, an alkaloid from the African iboga tree root bark, as the most potent and longest-acting psychedelic (24-36 hours), producing a closed-eye 'life review' experience where users re-examine past memories with detached empathy — described as '10 years of psychotherapy in a night.' He notes ibogaine carries cardiac risks manageable through EKG screening and reports dramatic preliminary results in veterans with PTSD and moral injury, including self-forgiveness for combat-related trauma. His team conducted the first human neuroimaging and neurocognitive study of ibogaine.
On ayahuasca, Williams explains its unique pharmacology — a two-plant combination where a reversible MAO inhibitor prevents GI breakdown of DMT, allowing it to cross the blood-brain barrier in a narrow therapeutic window. He references a Brazilian prisoner study where ayahuasca exposure significantly reduced recidivism rates compared to controls, raising questions about its effect on the behavioral and emotional drivers of criminal conduct. He emphasizes throughout that all these substances require strict medical supervision and are fundamentally incompatible with recreational use due to their power and risk profile.
Key Insights
- Williams argues that depression was recently added as the fourth major cardiovascular risk factor by the American Heart Association, alongside hypertension, hyperlipidemia, and diabetes, reflecting a direct physiological brain-heart connection rather than a merely psychological one.
- Williams claims that TMS stimulation of the dorsolateral prefrontal cortex produces measurable heart rate deceleration by propagating signals through the cingulate, amygdala, nucleus tractus solitarius, and into the vagus nerve — a finding replicated four to five times across multiple research groups.
- Williams contends that the serotonin deficiency model of depression is scientifically outdated and disempowering, and that SNT's rapid antidepressant effects — achieved without any pharmacological agent — actively challenge serotonin as the central mechanism of depression.
- Williams describes his SNT protocol as applying spaced learning theory to TMS: by compressing stimulation into 10 sessions per day over five days rather than once daily for six weeks, the treatment achieves 60-90% full remission rates in depression, with some patients maintaining remission for up to four years.
- Williams reports that psilocybin and SNT share a convergent antidepressant mechanism: both down-regulate connectivity between the subgenual anterior cingulate cortex and the default mode network, effectively decoupling negatively valenced mood states from self-representation.
- Williams states that MDMA-assisted therapy produced clinically significant PTSD improvement in approximately two-thirds of participants in the MAPS trials, with effects lasting potentially years — contrasting sharply with ketamine, whose antidepressant effects typically last only about ten days per infusion.
- Williams describes ibogaine as producing a 24-36 hour 'life review' in which users re-experience past memories with detached, third-party empathy, and reports that veterans in his preliminary study described forgiving themselves for combat-related moral injuries — an outcome he considers clinically dramatic.
- Williams argues that psychedelics are fundamentally incompatible with recreational use and require strict medical supervision, asserting that the current generation of psychedelic researchers — unlike those of the 1960s — clearly understands that these substances are too powerful for use outside tightly controlled clinical contexts.
Topics
Full transcript available for MurmurCast members
Sign Up to Access